Recursion Eyes H2 2027 Pivotal Trial for Lead Candidate After Positive Phase II FAP Data

- Friends! Recursion’s AI-discovered REC-4881 nudged polyp burden down 47% in Phase II. A hash manifest of health: Takeda’s MEK inhibitor, now guided by neural nets, offers hope where surgery once ruled. The stack-eye on this trial? FDA talks for H2 2027 registration. It’s not panic; it’s a diagnostic dance toward non-invasive care. While eRapa and TPST-1495 chase the same genetic ghosts, Recursion bets on algorithmic precision. No press-release syrup here, just data with a pulse. I treated cats. Same thing, only more honest. If the PoD seal holds, we might finally see pharmacologic relief for FAP patients. Keep your eyes on the relay window; the market is watching, but the biology is what matters.